Overview

A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B

Status:
Active, not recruiting
Trial end date:
2032-06-01
Target enrollment:
Participant gender:
Summary
Primary Objective: To evaluate the long-term safety and tolerability of SAR421869 in patients with Usher syndrome Type 1B Secondary Objective: To assess long-term safety and biological activity of SAR421869
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sanofi